EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Design, Synthesis, Antiproliferative Actions, and DFT Studies of New Bis–Pyrazoline Derivatives as Dual EGFR/BRAFV600E Inhibitors

Lamya H Al-Wahaibi, Hesham A Abou-Zied iD, Eman A M Beshr, Bahaa G M Youssif, Alaa M Hayallah iD, Mohamed Abdel-Aziz

International Journal of Molecular Sciences · 22.05.2023 · 24 (10) · 9104

DOI: 10.3390/ijms24109104 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 22.05.2023. Verfasst von Lamya H Al-Wahaibi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, College of Sciences, Princess Nourah bint Abdulrahman University, Riyadh 11564, Saudi Arabia. Hauptthemen laut MEDLINE: Cell Proliferation, Density Functional Theory, Drug Design, ErbB Receptors. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Princess Nourah bint Abdulrahman University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Some new Bis-pyrazoline hybrids 8–17 with dual EGFR and BRAFV600E inhibitors have been developed. The target compounds were synthesized and tested in vitro against four cancer cell lines. Compounds 12, 15, and 17 demonstrated strong antiproliferative activity with GI50 values of 1.05 µM, 1.50 µM, and 1.20 µM, respectively. Hybrids showed dual inhibition of EGFR and BRAFV600E. Compounds 12, 15, and 17 inhibited EGFR-like erlotinib and exhibited promising anticancer activity. Compound 12 is the most potent inhibitor of cancer cell proliferation and BRAFV600E. Compounds 12 and 17 induced apoptosis by increasing caspase 3, 8, and Bax levels, and resulted in the downregulation of the antiapoptotic Bcl2. The molecular docking studies verified that compounds 12, 15, and 17 have the potential to be dual EGFR/BRAFV600E inhibitors. Additionally, in silico ADMET prediction revealed that most synthesized bis-pyrazoline hybrids have low toxicity and adverse effects. DFT studies for the two most active compounds, 12 and 15, were also carried out. The values of the HOMO and LUMO energies, as well as softness and hardness, were computationally investigated using the DFT method. These findings agreed well with those of the in vitro research and molecular docking study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cell ProliferationDensity Functional TheoryDrug DesignErbB ReceptorsProto-Oncogene Proteins B-rafPyrazolesAntineoplastic AgentsHumansApoptosisCell LineCell SurvivalMolecular Docking SimulationStatic ElectricityStructure-Activity Relationshipbcl-2-Associated X ProteinProto-Oncogene Proteins c-bcl-2Caspase 3Caspase 8

Stichwörter der Autor:innen

ADMEDFTantiproliferativeapoptosishybridspyrazoline

Substanzen

ErbB ReceptorsProto-Oncogene Proteins B-rafPyrazolesAntineoplastic AgentsBAX protein, humanbcl-2-Associated X ProteinBCL2 protein, humanProto-Oncogene Proteins c-bcl-2BRAF protein, humanCASP3 protein, human

Autor:innen und Institutionen

  • Department of Chemistry, College of Sciences, Princess Nourah bint Abdulrahman University, Riyadh 11564, Saudi Arabia.
  • Medicinal Chemistry Department, Faculty of Pharmacy, Deraya University, Minia 61111, Egypt.
  • Medicinal Chemistry Department, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.
  • Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt.
  • Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Sphinx University, Assiut 71515, Egypt.

ORCID-Profile: Hesham A Abou-Zied, Alaa M Hayallah

Förderung

  • Princess Nourah bint Abdulrahman University

Zitieren

APA

Al-Wahaibi, L. H., Abou-Zied, H. A., Beshr, E. A. M., Youssif, B. G. M., Hayallah, A. M., & Abdel-Aziz, M. (2023). Design, Synthesis, Antiproliferative Actions, and DFT Studies of New Bis–Pyrazoline Derivatives as Dual EGFR/BRAFV600E Inhibitors. International Journal of Molecular Sciences, 24(10), 9104. https://doi.org/10.3390/ijms24109104

Vancouver

Al-Wahaibi LH, Abou-Zied HA, Beshr EAM, Youssif BGM, Hayallah AM, Abdel-Aziz M. Design, Synthesis, Antiproliferative Actions, and DFT Studies of New Bis–Pyrazoline Derivatives as Dual EGFR/BRAFV600E Inhibitors. International Journal of Molecular Sciences. 2023;24(10):9104. doi:10.3390/ijms24109104

BibTeX
@article{AlWahaibi2023,
  author = {Al-Wahaibi, Lamya H and Abou-Zied, Hesham A and Beshr, Eman A M and Youssif, Bahaa G M and Hayallah, Alaa M and Abdel-Aziz, Mohamed},
  title = {Design, Synthesis, Antiproliferative Actions, and DFT Studies of New Bis–Pyrazoline Derivatives as Dual EGFR/BRAFV600E Inhibitors},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {10},
  pages = {9104},
  doi = {10.3390/ijms24109104}
}
Kostenlos starten →